REG - Scancell Hlds - Director Dealing

Scancell HoldingsAnnouncement

21/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250521:nRSU4907Ja&default-theme=true

RNS Number : 4907J  Scancell Holdings Plc  21 May 2025

21 May 2025

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Director Dealing

 

Scancell (AIM: SCLP), the developer of novel immunotherapy products for the
treatment of multiple cancers, announces that Vulpes Testudo Fund, a fund
closely associated with Martin Diggle, Non- Executive Director, has purchased
497,764 ordinary shares of 0.9p each ('Ordinary Shares') in the Company
between 15 May 2025 and 20 May 2025 at a price of 9 pence per share. Following
the purchase, Vulpes Life Science Fund and Vulpes Testudo Fund together hold
130,884,801 ordinary shares representing 12.62% of the company.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING

 

MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Vulpes Testudo Fund
 2   Reason for the notification
 a)  Position/status                                              Fund closely associated with Martin Diggle, Non-Executive Director
 b)  Initial notification/Amendment                               Initial notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Scancell Holdings plc
 b)  LEI                                                          2138008RXEG856SNP666
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary Shares of 0.9 pence each
 b)  Identification Code                                          GB00B63D3314
 c)  Nature of the transaction                                    Purchase of Ordinary Shares

 d)  Price(s) and volume(s)                                       1.  9 pence  49,868
                                                                  2.  9 pence  402,952
                                                                  3.  9 pence  44,944
 e)  Aggregated information

     - Aggregated volume                                          497,764 Ordinary Shares

     - Price                                                      9 pence per Ordinary Share
 f)  Date of the transaction                                      1.  15 May 2025
                                                                  2.  16 May 2025
                                                                  3.  20 May 2025
 g)  Place of the transaction                                     London Stock Exchange, AIM

e)

Aggregated information

- Aggregated volume

- Price

 

497,764 Ordinary Shares

9 pence per Ordinary Share

f)

Date of the transaction

 1.  15 May 2025
 2.  16 May 2025
 3.  20 May 2025

g)

Place of the transaction

London Stock Exchange, AIM

 

 For further information, please contact:

 Scancell Holdings plc                                   +44 (0) 20 3709 5700
 Phil L'Huillier, CEO
 Sath Nirmalananthan, CFO
 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Panmure Liberum (Nominated Adviser and Joint Broker)    +44 (0) 20 7886 2500
 Emma Earl, Will Goode, Mark Rogers (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                          +44 (0) 20 3705 9330

 David Wilson, Claes Spang

 ICR Healthcare                                          +44 (0) 20 3709 5700

 Mary-Jane Elliott, Stephanie Cuthbert, Chris Welsh      scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 

About Scancell

Scancell (LSE:SCLP) develops immunotherapies for a Cancer-free future by
enhancing long-lasting tumour specific immunity. As a clinical stage
biotechnology company with deep roots in cancer immunology and translational
research, Scancell develops tumour targeted off-the-shelf vaccines, with
highly favourable safety and durable systemic immune responses. Scancell's
lead product, iSCIB1+, a DNA vaccine, is currently showing strong promise on
top of checkpoint therapies in a multi-arm phase 2 study in first-line
melanoma. The second vaccine, Modi-1, is being investigated in a phase 2 study
in a broad range of solid tumours. Scancell is also developing a pipeline of
high affinity antibodies targeting tumour specific glycans using its
proprietary platforms. Two of these antibodies are now being developed in
major biopharma partnerships, and a further two antibodies targeting lung and
epithelial cancers are actively being developed in-house.

https://www.scancell.co.uk (https://www.scancell.co.uk)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  DSHEAPSEALFSEFA